2026-2034年全球細胞治療用人類成分市場規模、佔有率、趨勢和成長分析報告

全球細胞治療用人源原料市場預計將從2025年的48.3億美元成長至2034年的223.9億美元，並預計在2026年至2034年間以18.58%的複合年成長率成長。全球細胞治療用人源原料市場正經歷強勁成長，這主要得益於先進細胞療法的研究進展和商業化進程。血清、生長因子和細胞培養基等人類來源的原料是細胞療法生產的關鍵。再生醫學和免疫療法領域投資的不斷增加也顯著推動了市場需求。

關鍵成長要素包括臨床試驗的擴展、細胞療法法規核准的增加以及對個人化醫療日益成長的關注。生物製藥公司正在加強供應鏈，以確保高品質、合規的原料供應。研究機構與產業相關人員之間合作的深化也進一步推動了市場發展。

未來，製造技術的進步以及CAR-T和幹細胞療法的商業化將創造巨大的商機。隨著對創新生技藥品需求的成長，全球醫療保健領域對人源細胞療法原料的需求預計將穩定擴大。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本節依據產品類型、應用、最終用戶和地區，將市場系統性地分類為若干關鍵細分市場。它揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球細胞療法用人類成分市場：依產品分類

• 市場分析、洞察與預測
• 細胞培養基
• 細胞培養用血清
• 細胞培養添加劑
• 試劑和緩衝液
• 其他成分

第5章：全球細胞治療用人類原料市場：依最終用途分類

• 市場分析、洞察與預測
• 生物製藥和製藥公司
• 合約研究組織 (CRO) 和合約行銷組織 (CMO)
• 學術和研究機構

第6章：全球細胞療法用人類成分市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Thermo Fisher Scientific Inc
  • Merck KGaA
  • Actylis
  • ACROBiosystems
  • STEMCELL Technologies Inc
  • Grifols SA
  • Charles River Laboratories International Inc
  • RoosterBio Inc
  • PromoCell GmbH
  • Danaher Corporation
  • BioIVT LLC
  • GeminiBio（Gemini Bioproducts LLC）
  • Akron Biotech
  • AllCells LLC
  • CGT Global

The global cell therapy human raw materials market size is expected to reach USD 22.39 Billion in 2034 from USD 4.83 Billion in 2025, growing at a CAGR of 18.58% during 2026-2034.The global cell therapy human raw materials market is witnessing strong growth driven by increasing research and commercialization of advanced cell-based therapies. Human-derived raw materials such as serum, growth factors, and cell culture media are essential in manufacturing cell therapies. Rising investments in regenerative medicine and immunotherapy are significantly boosting demand.

Major growth drivers include expanding clinical trials, increasing regulatory approvals for cell therapies, and rising focus on personalized medicine. Biopharmaceutical companies are strengthening supply chains to ensure high-quality and compliant raw materials. Growing collaborations between research institutions and industry players are further supporting market development.

In the future, advancements in manufacturing technologies and increasing commercialization of CAR-T and stem cell therapies will create significant opportunities. As demand for innovative biologics rises, the cell therapy human raw materials market is expected to expand steadily across global healthcare sectors.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Cell Culture Media
• Cell Culture Sera
• Cell Culture Supplements
• Reagents & Buffers
• Other Raw Materials

By End-Use

• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutions

COMPANIES PROFILED

• Thermo Fisher Scientific Inc., Merck KGaA, Actylis, ACROBiosystems, STEMCELL Technologies Inc., Grifols S.A., Charles River Laboratories International Inc., RoosterBio Inc., PromoCell GmbH, Danaher Corporation, BioIVT LLC, GeminiBio (Gemini Bioproducts LLC), Akron Biotech, AllCells LLC, CGT Global

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Cell Culture Media Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Cell Culture Sera Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cell Culture Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Reagents & Buffers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Raw Materials Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Biopharmaceutical & Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. CROs & CMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Academic & Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CELL THERAPY HUMAN RAW MATERIALS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Thermo Fisher Scientific Inc
  • 8.2.2 Merck KGaA
  • 8.2.3 Actylis
  • 8.2.4 ACROBiosystems
  • 8.2.5 STEMCELL Technologies Inc
  • 8.2.6 Grifols S.A
  • 8.2.7 Charles River Laboratories International Inc
  • 8.2.8 RoosterBio Inc
  • 8.2.9 PromoCell GmbH
  • 8.2.10 Danaher Corporation
  • 8.2.11 BioIVT LLC
  • 8.2.12 GeminiBio (Gemini Bioproducts LLC)
  • 8.2.13 Akron Biotech
  • 8.2.14 AllCells LLC
  • 8.2.15 CGT Global